ライフサイエンスコーパス: itching

1 nd induced pathophysiological responses (ie, itching).

2 1, with higher scores indicating more severe itching).

3 An alternative scoring is based on itching.

4 were dryness, redness, burning sensation and itching.

5 ress has been made to uncover the mystery of itching.

6 sease characterized by recurrent episodes of itching.

7 herpesvirus infections is peripheral pain or itching.

8 symptoms: rhinorrhoea, blockage, sneezing or itching.

9 at is characterized by recurrent episodes of itching.

10 provide new insight into mechanisms of skin itching.

11 nt sensations, as has been shown for pain or itching.

12 hypersensitivity, tooth pain, swelling, and itching.

13 n blood pressure of > or =20% or intolerable itching.

14 motor skills, 48.7 vs 53.0 [P = .002]; pain/itching, 15.8 vs 33.5 [P < .001]; and worry/concern, 31.

15 The most common adverse events were itching (211 patients in the imiquimod group vs 129 in t

16 Rash (84 reports), itching (46 reports), and vomiting (30 reports) were the

17 minant disorder associated with chronic skin itching and deposition of epidermal keratin filament-ass

18 aracterized by generalized redness, scaling, itching and increased numbers of circulating atypical T

19 Our results indicate that TLR7 mediates itching and is a potential therapeutic target for anti-i

20 Manifestations range from itching and minor pain to neurological symptoms, cardiac

21 nd elevated IgM levels, which correlate with itching and pathology.

22 reased quality-of-life impairment, including itching and sexual dysfunction.

23 anogenital area, where it causes intractable itching and soreness.

24 gastrointestinal symptoms), and reduction in itching and whealing after standardized skin provocation

25 Itching and/or burning skin occurred in a sizable percen

26 adherence of the eyelids on waking, lack of itching, and absence of a history of conjunctivitis are

27 Dry skin, fatigue, itching, and bone/joint pain each were reported by > or

28 ns with groin venous access, lower extremity itching, and deep venous thrombosis.

29 Injection site pain, itching, and erythema (mostly mild) were the only solici

30 by elevated serum bile acid concentrations, itching, and fat malabsorption.

31 couver Scar Scale (VSS), asked to rate their itching, and genotyped for 8 MC1R SNPs.

32 d skin resulting in scarring due to constant itching, and hyperplasia of lymphoid cells, haematopoiet

33 o 5-point scores for severity of congestion, itching, and rhinorrhea), A(min) (in square centimeters)

34 onsisting of blocked nose, runny nose, nasal itching, and sneezing was used to evaluate symptoms.

35 emotional behavior, family functioning, pain/itching, appearance, satisfaction with care, and worry/c

36 01), and the occurrence of perianal rash and itching as well as the use of protective pads decreased

37 eficits were accompanied by greatly enhanced itching, as suggested by (1) sensitization of both hista

38 pain, tenderness, and (much less frequently) itching at the injection site.

39 The most common adverse event was mild itching at the tick attachment site.

40 on, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, a

41 neous nerves and an accompanying increase in itching, both of which were abolished in the absence of

42 d with intense acute flares of inflammation, itching, burning pain, vasodilatation, and redness of th

43 incidence of local side effects (redness and itching) but a similar incidence of systemic side effect

44 However, chronic persistent itching can be devastating.

45 understanding the pathophysiology of chronic itching conditions, will hopefully contribute to the dev

46 ically used for chronic hepatic diseases and itching dermatitis, modulates the pathological processes

47 For example, our results suggest that itching during inflammatory skin diseases such as atopic

48 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibitors) are also being studied.

49 requently considered but may cause localized itching (especially in the genital area) and generalized

50 luded rhinorrhoea, forehead/facial sweating, itching eye, eyelid oedema, sense of aural fullness and

51 nth history of epigastric pain and jaundice, itching, flushing, cough and wheezing.

52 uded additional VAS items (burning/stinging, itching, foreign body sensation, eye discomfort, photoph

53 bjective adverse events (erythema, swelling, itching, headache, root hypersensitivity, or pain) were

54 Later, she felt itching in her mouth.

55 After that she felt discomfort and itching in her oral cavity.

56 ythematoedematovesicous lesions with intense itching in the acute phase.

57 ts in abnormal immune responses and constant itching in the skin.

58 tion of these individuals seek medical help; itching is the most consistent sign in allergic conjunct

59 Itching is the predominant symptom of skin disease but i

60 "catastrophizing cognitions" with respect to itching (Juckreiz-Kognitions-Fragebogen questionnaire),

61 signs can include intense vulvar and vaginal itching, low back pain, uterine cramps, fetal distress,

62 Asian race, absence of itching, lung disease, low serum albumin levels, low pla

63 However, a patient's lack of itching makes candidiasis less likely (range of LRs, 0.1

64 Ocular itching (n = 101; 83.5%) was the predominant symptom and

65 ing (n = 10; 23%), photophobia (n = 6; 14%), itching (n = 4; 9%), swelling (n = 2; 5%), and infection

66 ermittent exposure to seasonal pollen causes itching, nasal congestion, and repeated sneezing, with p

67 ifitegrast-treated participants at day 42 in itching (nominal P = 0.0318), foreign body sensation (no

68 0.3), and sneeze of -8.8 (SE, 1.5); group 2, itching of -0.6 (SE, 0.3), rhinorrhea of -0.8 (SE, 0.3),

69 cebo: group 1, congestion of -0.7 (SE, 0.3), itching of -1.0 (SE, 0.3), rhinorrhea of -1.3 (SE, 0.3),

70 tive reactions ranging in severity from mild itching of the oral mucosa to bronchospasm.

71 mune and inflammatory disorders and constant itching of the skin.

72 Such release may contribute to common itching or intensify the inflammatory response in vivo.

73 Positive criteria are based on itching or quoted according to a composite score.

74 gnificant difference in disability, fatigue, itching, or patient or clinician global disease severity

75 Itching, or pruritus, is defined as an unpleasant cutane

76 color, such as skin irritation, tenderness, itching, or skin becoming darker, may allow physicians t

77 dy outcomes: coping behavior with respect to itching (P < .001), quality of life assessed by using th

78 They included headache, swelling, itching, pain, and root hypersensitivity.

79 as preferred over placebo, for the relief of itching, pain, discomfort, edema, and redness in respons

80 owever, there was a dose-related increase in itching, pain, edema, and staining of the anogenital ski

81 ars produce significant morbidity, including itching, pain, stiffness, and contracture, but best mana

82 cratching deficits in response to all of the itching (pruritogenic) stimuli tested, irrespective of t

83 ory nerve substance P and, in turn, increase itching responses.

84 mptoms of allergic rhinitis, including nasal itching, rhinorrhea, and sneezing, although most agents

85 Contagious behaviors such as yawning and itching/scratching have mirror-like properties and clear

86 s of this class of neurons parallel the pure itching sensation this stimulus elicits in humans, and m

87 n the tissues involved such symptoms include itching, sneezing, irritation, vasodilation, and reflex

88 s characterized by typical symptoms of nasal itching, sneezing, watery discharge and congestion.

89 changes (evolving) of size, shape, symptoms (itching, tenderness), surface (especially bleeding), and

90 ts on the overall DLQI (47% vs 14%; P<.001), Itching VAS (38% vs -0.2%; P<.001), and PSA frequency an

91 Perianal itching was the only side effect reported and was noted

92 vements in quality of life, symptom control (itching, wheals and flares, flushing, tachycardia, and h